Objective . To analyse the prevalence of GAD and other anxiety disorders, as well as sensitivity and specifi city of GAD-7 among high utilizers of health care. Setting . Four municipal health centres in Northern Finland. Subjects . A psychiatric interview was conducted for 150 high utilizers of health care. Main outcome measures . Prevalence of GAD as well as sensitivity and specifi city of GAD-7. Results . The prevalence of GAD was 4% in this study group of Finnish high utilizers of health care. The sensitivity of GAD-7 was 100.0% (95% CI 54.1 -100.0) and the specifi city of GAD-7 was 82.6% (95% CI 75.4 -88.4) with a cut-off point of 7 or more. Conclusion . GAD is rather common among high utilizers of primary care, although the prevalence of 4% is lower than that previously reported. GAD-7 is a valid and useful tool for detecting GAD among primary health care patients.
Introduction
Generalized anxiety disorder (GAD) is highly prevalent in the general population with a current prevalence of 2 -3% and a lifetime prevalence of over 5% [1 -3] . According to international studies, GAD is especially frequent among primary care attenders with an 8% prevalence [3, 4] . In Finland, the age-standardized prevalence rate of GAD among primary health care patients has been reported to be 4.1% for males and 7.1% for females [5] . Patients with GAD often present with somatic and sleeping problems and only rarely complain of anxiety symptoms directly, which makes detecting of this disease challenging [1] . Therefore, it is no surprise that GAD is poorly detected by health care professionals [6] . Earlier studies have shown patients with GAD to have a high rate of primary care visits [6] . In an American primary care study, 51% of high utilizers were identifi ed as distressed by their physician, or had elevated scores on the SCL (Symptom Checklist-90-R) anxiety and
Material and methods

Study sample
The study was conducted in four municipal health centres (Ii, Pudasj ä rvi, Utaj ä rvi, Vaala) in Northern Finland.
The data on high utilizers of health care were collected retrospectively from the medical records of municipal health centres and medical reports from outpatient visits to Oulu University Hospital (providing secondary health care facilities for all of the municipal health centres participating in this study) before two years of study in 2006 -2008 . The patients ' inclusion criteria were being at least 18 years of age and having Ն 8 visits per year to the general practitioner (GP) in the local health centre or Ն 4 visits per year to the university hospital. The total number of all frequent attenders (FA) in the selected health centres during 1 August 2006 -31 July 2008 was 3319 (see Figure 1) .
Exclusion criteria included visits due to pregnancy or delivery, serial treatment for the same illness, terminal hospice, cancer palliative care, psychotic illness, dementia, mental retardation, inability to give informed consent, and other study intervention at the same time or just prior to this study.
All the participating health centres had a nurse as a case manager, who telephoned the identifi ed FA and invited him/her to a consultation. The case manager verifi ed patients ' eligibility for the study, requested their written informed consent for the study, and helped in fi lling in a semi-structured postal questionnaire, which was sent to the partici- symptom criteria for GAD (8) . It asks how often the patient has been bothered by seven different symptoms of anxiety during the last two weeks with response options such as: " not at all " , " several days " , " more than half the days " , and " nearly every day " scored as 0, 1, 2, and 3, respectively (8) . The Finnish translation of GAD-7 has been done by Finnish psychiatry professionals.
Statistical methods
Results were expressed as means with standard deviation (SD) and 95% confi dence intervals (CIs), and as medians with interquartile range (IQR). Statistical comparison between the groups was performed by t-test or chi-squared test, when appropriate.
Receiver-operating characteristic (ROC) curves were constructed to obtain the area under the curve (AUC), which is a criterion for test quality. We defi ned the best cut-off value as the value with the highest accuracy that maximizes Youden ' s index. Sensitivity, specifi city, positive predictive value, likelihood ratio, Youden ' s index, and their 95% CI values were calculated.
Results
Demographic characteristics of the study population are presented in Table I . Our study population consisted of 46 (30.7%) males and 104 (69.3%) females. The mean age of our study population was 62.7 (SD 13.0) years. The prevalence of GAD according to the DSM-IV (obtained by the MINI) among our study population was 4.0% (1. 5 -8.5 ). According to patient questionnaires enquiring about lifetime psychiatric diagnoses, none of these GAD diagnoses was previously detected. The prevalence of panic disorder and other anxiety disorders was 6.7 (3.2 -11.9 ) and 6.7 (3.2 -11.9), respectively. Table II presents the measures of validity (sensitivity, specifi city, and positive likelihood ratios) for different cut-off points of the GAD-7 and GAD-2 in patients with GAD, panic disorder, and other anxiety disorders. In GAD, Youden ' s index was the highest (0.83) for the cut-off point 7 or more for GAD-7. The sensitivity and specifi city parameters for this cut-off point were 100.0% (95% CI 54.1% -100%) and 82.6% (95% CI 75.4% -88.4%), respectively; its positive likelihood ratio was .
In panic disorder and other anxiety disorders, Youden ' s index was the highest (0.49 and 0.53, respectively) for the cut-off points 6 and 5, respectively. In panic disorder, the sensitivity and specifi city parameters for this cut-off point of 6 or more were 70.0% (95% CI 34.8% -93.3%) and 79.3% (95% CI 71.6% -85.7%), respectively. Its positive likelihood ratio was 3.4 (95% CI 2.01 -5.68). The sensitivity and specifi city for other anxiety disorders with the cut-off point of 5 or more were 80.0% (95% CI 44.4% -97.5%), 73.6% (95% CI 65.5% -80.7%), respectively. The positive likelihood ratio was 3.0 (95% CI 2.00 -4.59).
For the GAD-2 scale, Youden ' s index was highest with a cut-off point Ն 3 in GAD, Ն 1 in panic disorder, and Ն 1 in other anxiety disorders. The corresponding sensitivity, specifi city, and positive likelihood ratios are presented in Table II .
In ROC analysis (Figure 2a ), for GAD-7, the area under the curve in GAD, panic disorder, and other anxiety disorders was 0.96 (95% CI 0.91 -1.00), 0.79 (95% CI 0.65 -9.93), and 0.81 (95% CI 0.67 -0.95), respectively. The corresponding fi gures for GAD-2 were 0.91 (95% CI 0.78-1.0), 0.74 (95% CI 0.63 -0.85), and 0.75 (95% CI 0.65 -0.86), respectively (Figure 2b) . Table III summarises this data.
Discussion
Statement of principal fi ndings
To the best of our knowledge, this was the fi rst study investigating the prevalence of GAD in primary care in Finland by using a structured and validated psychiatric interview (MINI). The prevalence of GAD was 4%. It should be noted that all of the GAD diagnoses were undetected according to the self-questionnaires. We also showed that GAD-7 and GAD-2 are valid instruments for detecting GAD in primary health care patients.
Strengths and weaknesses of the study
The strength of our study was that it was among the fi rst globally investigating the prevalence of GAD among high utilizers of health care. Second, the diagnoses were based on a psychiatric interview with the help of a semi-structured and validated instrument (MINI). What is more, this study also has practical implications by showing the validity of the Finnish version of GAD-7 as a screening tool for GAD and other anxiety disorders among primary care patients.
Our study also has some limitations. A small sample size limits the generalization of our results. Not all the patients from the original sample of 286 high utilizers participated in the psychiatric interview. It is notable, however, that the patients not attending the psychiatric interview do not differ signifi cantly from our fi nal study population with regard to variables such as quality of life, somatization, mood, and daily functioning. Therefore, the group of patients included in the psychiatric interviews is representative of the total sample of 286 patients.
The health care utilization data were determined four years prior to psychiatric interviews, which means that not necessarily the whole study population were high utilizers at the point of interview. However, earlier studies indicate that up to 40% of high utilizers of health care still remain high utilizers in the following year (16). Sensitivity ( 
Comparison with existing literature
Earlier studies indicated a higher prevalence of GAD than that observed in this investigation because in a European study primary care attenders have been reported to have a prevalence of 8% [3, 4] . In Finland, the prevalence of current GAD among primary care attenders was 4.1% for males and 7.1% for females in an earlier study based on self-questionnaires [5] . In a population study, the 12-month prevalence of GAD in Finland was 1.3% based on CIDI interview [17] . Only a few earlier studies exist investigating the prevalence of GAD specifi cally among high utilizers of health care, and major methodological differences make comparison of these diffi cult. An American study investigated the prevalence of GAD among distressed high utilizers of health care and reported a prevalence of 21.8% for GAD [7] . The high prevalence is explained by their approach of focusing only on distressed high utilizers of health care. A Canadian study based on the self-reported worry and anxiety questionnaire (WAQ) showed that patients with fi ve or more yearly physician consultations were 3.95 times more likely to have positive results for GAD with a rate of 35.2% (18). Our study was based on a structured psychiatric interview giving a reliable diagnosis rather than symptoms only. The detected prevalence of 4% in this study is close to what had been detected earlier among all primary care attenders, and it is possible that a smaller proportion of patients with GAD have attended the present study due to their anxiety.
GAD-7 is a new tool that is designed for screening for GAD and other anxiety disorders in primary care. Our data shows that the Finnish translation of GAD-7 and its shorter version, GAD-2, are valid tools with high sensitivity and specifi city for GAD. The highest Youden ' s index was obtained with a cutoff point of 7. This is lower than in the original study, in which the cut-off point was defi ned as a total score of 10 (8) . Additional data are needed to further defi ne the optimal cut-off point for the Finnish version. GAD-7 and GAD-2 are also valuable for detecting panic disorder and other anxiety disorders, although sensitivity and specifi city are lower than for GAD. This is in line with earlier studies (10) .
Implications for clinical practice and future research
GAD is a severe condition with a major negative effect on functioning and quality of life [19] . Based on our data here and earlier reports, GAD is rather Figure 2 . ROC for GAD, panic disorder and other anxiety disorder using a) GAD-7 and b) GAD-2.
prevalent among primary care patients, especially those with frequent visits. Therefore, it is important that the condition is recognized by health care professionals. GAD-7 is a valid and useful tool for screening for GAD and other anxiety disorders in primary health care. Additional studies are needed to further elucidate the psychometric properties of GAD-7.
Conclusions
GAD and also other anxiety disorders are rather common among high utilizers of health care. The Finnish version of GAD-7 is a valid instrument for detecting GAD in primary health care.
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